Brokers Set Expectations for Xeris Biopharma Q2 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Investment analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for Xeris Biopharma in a research note issued on Monday, May 12th. Leerink Partnrs analyst R. Ruiz anticipates that the company will post earnings per share of ($0.01) for the quarter. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share. Leerink Partnrs also issued estimates for Xeris Biopharma’s Q3 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.00 EPS, FY2026 earnings at $0.20 EPS, FY2027 earnings at $0.40 EPS and FY2028 earnings at $0.65 EPS.

XERS has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Oppenheimer upped their target price on Xeris Biopharma from $6.00 to $7.00 and gave the stock an “outperform” rating in a research note on Friday, May 9th. Piper Sandler reissued a “neutral” rating and issued a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Jefferies Financial Group reissued a “buy” rating and issued a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Finally, Craig Hallum upped their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $6.25.

Xeris Biopharma Stock Performance

XERS stock opened at $4.79 on Thursday. Xeris Biopharma has a one year low of $1.86 and a one year high of $6.07. The firm’s fifty day moving average is $4.71 and its 200 day moving average is $3.89. The firm has a market cap of $749.08 million, a PE ratio of -10.64 and a beta of 1.10.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. The firm had revenue of $57.80 million for the quarter, compared to analyst estimates of $57.61 million.

Hedge Funds Weigh In On Xeris Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of the business. NewEdge Advisors LLC acquired a new stake in Xeris Biopharma in the 4th quarter valued at about $34,000. R Squared Ltd acquired a new position in shares of Xeris Biopharma during the 4th quarter worth approximately $42,000. Cibc World Markets Corp purchased a new stake in shares of Xeris Biopharma in the fourth quarter valued at approximately $44,000. Raymond James Financial Inc. acquired a new stake in shares of Xeris Biopharma in the fourth quarter valued at approximately $45,000. Finally, Two Sigma Advisers LP acquired a new stake in shares of Xeris Biopharma in the fourth quarter valued at approximately $47,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Beth Hecht sold 40,000 shares of the stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the sale, the insider now directly owns 1,353,510 shares in the company, valued at $7,349,559.30. This represents a 2.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 6.47% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.